These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 37822882)

  • 1. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma.
    Zhang HB; Pan JY; Zhu T
    Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882
    [No Abstract]   [Full Text] [Related]  

  • 2. Unlocking the Potential of Disulfidptosis-Related LncRNAs in Lung Adenocarcinoma: A Promising Prognostic LncRNA Model for Survival and Immunotherapy Prediction.
    Nie X; Ge H; Wu K; Liu R; He C
    Cancer Med; 2024 Oct; 13(20):e70337. PubMed ID: 39431755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.
    Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L
    Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
    Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
    Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
    Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
    Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of lncRNA prognostic model related to disulfidptosis in lung adenocarcinoma.
    Zhang L; Wang S; Wang L
    Heliyon; 2024 Aug; 10(15):e35657. PubMed ID: 39170273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiomics Analysis of Disulfidptosis Patterns and Integrated Machine Learning to Predict Immunotherapy Response in Lung Adenocarcinoma.
    Liu J; Li H; Zhang N; Dong Q; Liang Z
    Curr Med Chem; 2024; 31(25):4034-4055. PubMed ID: 38685772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disulfidptosis‑related lncRNA prognosis model to predict survival therapeutic response prediction in lung adenocarcinoma.
    Sun X; Li J; Gao X; Huang Y; Pang Z; Lv L; Li H; Liu H; Zhu L
    Oncol Lett; 2024 Aug; 28(2):342. PubMed ID: 38855504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering disulfidptosis: Uncovering a lncRNA-based signature for prognostic assessment, personalized immunotherapy, and therapeutic agent selection in lung adenocarcinoma patients.
    Ma C; Zhao H; Sun Y; Ding W; Wang H; Li Y; Gu Z
    Cell Signal; 2024 May; 117():111105. PubMed ID: 38369264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer.
    Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
    Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
    Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatics construction and experimental validation of a cuproptosis-related lncRNA prognostic model in lung adenocarcinoma for immunotherapy response prediction.
    Li L; Cai Q; Wu Z; Li X; Zhou W; Lu L; Yi B; Chang R; Zhang H; Cheng Y; Zhang C; Zhang J
    Sci Rep; 2023 Feb; 13(1):2455. PubMed ID: 36774446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-talk between necroptosis-related lncRNAs to construct a novel signature and predict the immune landscape of lung adenocarcinoma patients.
    Wu J; Song D; Zhao G; Chen S; Ren H; Zhang B
    Front Genet; 2022; 13():966896. PubMed ID: 36186456
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma.
    Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G
    Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value and Immune Landscapes of Four Types of RNA Modification Writer-Related LncRNAs Signature in Lung Adenocarcinoma.
    Qian Y; Zhang Q; Ren Y; Cao L; Zheng S; Li B; Wu X; Meng Z; Xu K
    J Cancer; 2024; 15(15):4818-4837. PubMed ID: 39132150
    [No Abstract]   [Full Text] [Related]  

  • 16. Crosstalk among disulfidptosis-related lncRNAs in lung adenocarcinoma reveals a correlation with immune profile and clinical prognosis.
    Liu S; Wang S; Guo J; Wang C; Zhang H; Lin D; Wang Y; Hu X
    Noncoding RNA Res; 2024 Sep; 9(3):772-781. PubMed ID: 38590434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
    Ma C; Li F; Gu Z; Yang Y; Qi Y
    Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
    [No Abstract]   [Full Text] [Related]  

  • 18. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
    Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
    Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma.
    Fang X; Huang E; Xie X; Yang K; Wang S; Huang X; Song M
    Front Genet; 2022; 13():951311. PubMed ID: 36406130
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of a disulfidptosis-related lncRNA prognostic signature for enhanced prognostic assessment and therapeutic strategies in lung squamous cell carcinoma.
    Zhu A; Zong Y; Gao X
    Sci Rep; 2024 Aug; 14(1):17804. PubMed ID: 39090162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.